Under this new agreement, the parties will leverage AdvanCell’s proprietary Pb-212 production technology and radionuclide development infrastructure and Lilly’s drug candidate programs and ...

Announced on February 10, Eli Lilly is expanding its collaboration with AdvanCell to advance targeted alpha therapies for cancer treatment. By using AdvanCell’s Pb-212 production technology and ...

Eli Lilly inks duo of deals, teaming with AdvanCell, OliX to push deeper into radiopharma, MASH FXRs, short for farnesoid X receptors, are nuclear receptors mainly expressed in the liver and ...

collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd. Eli Lilly and Company was founded in 1876 and is ...

Dealmaking in the Asia Pacific (APAC) region took off this week, with the latest showcasing Genome & Co.’s licensing deal with Ellipses Pharma Ltd. for GENA-104, a phase I-ready immuno-oncology asset, ...

Circular Genomics recently moved its headquarters to Lilly Gateway Labs, aiming to enhance its Alzheimer's disease ...

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology ...

SYDNEY--(BUSINESS WIRE)--AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, today announced the successful completion of an oversubscribed US$112 ...